United States Patent 5,324,824 Scope, Claim Chart, and Patent Landscape for Lyophilized Isonitrile–Radionuclide Coordination Kits

Executive summary. US Patent 5,324,824 claims a lyophilized kit used to form a coordination complex between an isonitrile ligand and a radioisotope radionuclide (explicitly including Tc-99m and other transition-metal radionuclides). The kit claim is tightly structured around two lyophilized components: (i) a predetermined quantity of an adduct of copper and the isonitrile ligand and (ii) a predetermined quantity of a reducing agent (example: stannous ion) that reduces a selected radionuclide so the radionuclide replaces copper to form the final radiometal complex. Dependent claims narrow to Tc-99m, specific isonitrile substituent structures, stannous ion, and sealed, non-pyrogenic sterilized containers.

How broad is US 5,324,824’s claim scope for lyophilized isonitrile radionuclide kits?

Independent claim 1: what the patent requires, element-by-element

Claim 1 is a kit claim with functional language tied to in-kit chemistry. It requires:

A “lyophilized kit” for preparing a coordination complex.
The coordination complex must involve:
- an isonitrile ligand, and
- a radionuclide selected from a defined class: radioactive isotopes of
  Tc, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Ta.
The kit comprises a lyophilized predetermined quantity of:
- (a) an adduct of a complex of copper and the isonitrile ligand, and
- (b) a predetermined quantity of a reducing agent.
The reducing agent must be capable of reducing a predetermined quantity of a preselected one of the listed radionuclides to form the complex by replacing copper from the ligand with that radionuclide.

Claim structure consequence. The patent is not just claiming the final coordination complex. It claims the manufactured, packaged kit with defined chemical roles: a preformed Cu–isonitrile adduct plus a reduction system that enables in-kit metal exchange with radionuclides.

Key claim construction levers

“Lyophilized kit” narrows to freeze-dried, packaged products rather than solution kits.
“Predetermined quantity” narrows to kits formulated with fixed dosing amounts (commercial kit format).
“Adduct of a complex of copper and said isonitrile ligand” narrows the starting species to a copper-isocyanide (isonitrile) adduct or adduct-like copper complex that is recoverable upon reconstitution.
“Reducing agent capable of reducing… said radionuclide to form said complex by replacing the copper” reads as a requirement that the kit’s reducer is functionally competent to drive radionuclide incorporation via metal exchange.

Functional language boundaries

Claim 1 includes a functional step but in a kit context. The “capable of reducing” language is broad enough to cover multiple reducing agents that can reduce the specified radionuclides under the kit’s conditions, but the chemistry must still culminate in replacement of copper to produce the coordination complex.

What radionuclides and isonitrile ligands does US 5,324,824 cover?

Radionuclide coverage: explicit metal class list

Claim 1 expressly covers kit use with radionuclides from the following element families:
Tc, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Ta.

This is a notable breadth: it is not restricted to Tc-99m only. The kit can be used as a general radiochemistry formulation platform across a defined set of transition metals.

Dependent claim 2: Tc-99m

Claim 2 narrows claim 1 by requiring the radionuclide is Tc-99m. This is a commercially important specialization because Tc-99m is the dominant diagnostic radioisotope.

Dependent claim 3: isonitrile ligand structural constraint

Claim 3 requires the isonitrile ligand has formula:

CNR, where R is butyl or butyl having an alkyl ether or alkyl ester substitution.

Scope effect. This clause narrows the isonitrile substituent. It ties the claimed ligand chemistry to specific hydrophobic or functionality-modified butyl-containing substituents that likely tune coordination and in vivo behavior.

What reducing agents are claimed, and how does stannous ion limit or broaden coverage?

Dependent claim 4: stannous ion

Claim 4 specifies the reducing agent is stannous ion.

Interpretation for scope:

Claim 1 is not limited to stannous ion; it claims a “reducing agent” broadly, limited only by functional capability to enable radionuclide incorporation replacing copper.
Claim 4 narrows that broad class to stannous ion. That gives the patent a fallback position on a common Tc radiopharmaceutical reduction system component.

What container and handling limitations are claimed for US 5,324,824?

Dependent claim 5: sealed, non-pyrogenic sterilized container

Claim 5 adds:

sealed
non-pyrogenic
sterilized container

This is typical for injectable radiopharmaceutical kit formats. It also provides an additional infringement pathway because a competing product must not only have the same lyophilized formulation chemistry but also match container compliance format.

Claim chart for US 5,324,824 (practical infringement mapping)

Claim requirement	What it covers	Typical design-around implications
Lyophilized kit	freeze-dried packaged reagents	Solution-form kits may avoid literal “lyophilized kit”
Coordination complex of isonitrile + radionuclide	end product must be a radionuclide coordination complex	Avoid isonitrile ligands or avoid radionuclide metal exchange path
Radionuclide from listed elements	broad element coverage beyond Tc-99m	Use radionuclides outside the listed element class
Lyophilized predetermined quantity of Cu-isocyanide adduct	preformed copper complex + isonitrile ligand is essential	Use alternative starting metal form (not a copper complex/adduct)
Lyophilized predetermined quantity of reducing agent	reducer is mandatory kit component	Omit reducer and rely on external reducer (risk under doctrine of equivalents)
Reducer reduces predetermined quantity of preselected radionuclide	functional step required	Use a reduction system that does not replace copper in the claimed manner
Replacing copper from the ligand with radionuclide	metal-exchange mechanism is central	Use ligands that bind radionuclide without copper exchange
Dep. claim 2: Tc-99m	narrow specialization	Only cover other radionuclides to avoid this dependent claim
Dep. claim 3: ligand is CNR with R limited	ligand structural limitation	Use different isonitrile substituent patterns
Dep. claim 4: reducing agent is stannous ion	narrower chemistry limitation	Use a different reducer not stannous ion
Dep. claim 5: sealed non-pyrogenic sterilized container	container/format	Use different container specification (hard medically, but possible)

How strong is the patent estate based on claim breadth and narrowing dependencies?

Strength signals in claim language

Strong breadth in claim 1: covers multiple radionuclide metals via an explicit list and allows any “isonitrile ligand” without structural limitation at the independent claim level.
Built-in fallback positions: dependent claims 2-5 add narrowing hooks to support infringement in common commercial embodiments (Tc-99m, butyl-substituted isonitriles, stannous ion reduction, and compliant injectable kit containerization).

Main vulnerability points

Kit + copper-adduct anchoring: if competitors do not start from a copper-isocyanide adduct and instead use another precursor (e.g., direct radiometal complexation without copper exchange), they can argue non-infringement of claim 1.
“Replacing copper” requirement: if the mechanism differs from copper replacement (even if end products are similar), the claim 1 functional requirement becomes a focal litigation battleground.

What patent landscape surrounds US 5,324,824 for isonitrile radiopharmaceutical kits in the US?

What the patent is likely positioned against (high-probability landscape buckets)

Because US 5,324,824 is a kit claim anchored to an isonitrile ligand + metal radionuclide coordination complex prepared via Cu-to-radionuclide exchange, the relevant prior and adjacent US patent landscape typically clusters into four categories:

Isonitrile ligand structures for Tc-99m and related metals
- patents covering CNR isonitrile ligands, especially substituted butyl or ester/ether variants.
Kit formulations and reduction systems for Tc-99m radiopharmaceuticals
- stannous ion reduction, alternatives, and lyophilized kit components.
Radiometal complex formation mechanisms (transchelation, metal exchange)
- patents claiming copper-mediated or alternative precursor exchange pathways.
Delivery format and container compliance
- non-pyrogenic, sterilized, sealed, and lyophilized kit manufacturing.

How to use the claim structure to search the landscape

A landscape search for close variants typically uses:

US patents mentioning “lyophilized kit”, “isonitrile”, “copper”, “reducing agent”, “stannous ion”, and “Tc-99m”.
Claims describing metal exchange where a precursor includes copper and radionuclide incorporation occurs via copper replacement.
Ligand formula search for CNR, butyl, and ether/ester substituted butyl isonitriles.

What can’t be produced from the provided record

No bibliographic details (assignee, filing date, prosecution history, cited references, maintenance status, or related continuations/divisionals) were provided, and no dataset was supplied to validate other patents’ claim texts or dates. Without that, a complete, citation-level US landscape mapping (specific patent numbers, assignees, expiration dates, and litigation files) cannot be generated accurately.

Accordingly, the only definitive analysis that can be produced here is claim scope based strictly on the claim text supplied.

When does US 5,324,824 lose exclusivity in practice?

A correct exclusivity and expiration analysis requires patent filing/priority dates, term adjustments, and whether maintenance fees were paid. Those data are not present in the supplied record. Without them, any date stated would be speculative.

What claim-design risks exist for generic or “work-alike” radiopharmaceutical kits?

For a competitor kit builder

To avoid claim 1, a competitor typically needs to alter at least one of the following claim-critical anchors:

Provide reagents that are not lyophilized in the claimed form.
Avoid providing a lyophilized Cu–isonitrile adduct as the precursor.
Use a pathway where copper is not replaced by the radionuclide in the described manner.
Change ligand chemistry so it falls outside the dependent claim 3 constraints if targeting Tc-99m implementations.
Use a reducer not falling within dependent claim 4 (stannous ion), while still achieving kit chemistry.

Key Takeaways

US 5,324,824 is a kit patent focused on preparing isonitrile–radionuclide coordination complexes from a lyophilized copper-isocyanide adduct and a reducing agent that enables radionuclide incorporation by replacing copper.
Claim 1 is broad across a defined list of radionuclide elements and covers any isonitrile ligand, while dependent claims lock onto Tc-99m, butyl/substituted butyl isonitriles (CNR), stannous ion, and sealed non-pyrogenic sterilized containers.
The copper-adduct + copper replacement mechanism is the main infringement focal point for work-alikes; shifting precursor chemistry or exchange mechanism is the most direct design-around route.

FAQs

If a competitor uses a non-copper radionuclide precursor but yields the same final Tc-99m isonitrile complex, does it avoid US 5,324,824?
Claim 1 requires a kit comprising a lyophilized copper-is-onitrile adduct and radionuclide formation by replacing copper; non-copper precursors create a literal non-infringement argument.
Does using a reducer other than stannous ion infringe dependent claim 4?
Dependent claim 4 requires stannous ion, so a different reducer can avoid that specific dependent claim, while claim 1 may still apply if the alternative reducer is a “reducing agent” capable of enabling copper replacement.
Can a kit that is lyophilized but reconstitutes without “predetermined quantity” avoid claim 1?
Claim 1 requires “lyophilized predetermined quantity” of the copper-adduct and the reducing agent.
How does the ligand substitution limitation in claim 3 affect infringement analysis?
Claim 3 limits the isonitrile to CNR with butyl or butyl with alkyl ether/alkyl ester substitution, so kits using other R groups can avoid claim 3 but may still infringe claim 1.
Is Tc-99m the only radionuclide covered by the patent?
No. Claim 1 covers radionuclides selected from a broad element list; claim 2 specifically narrows to Tc-99m.

References (APA)

United States Patent 5,324,824. (Provided claim text).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	63311	⤷ Start Trial
Australia	587484	⤷ Start Trial
Australia	6087886	⤷ Start Trial
Canada	1293729	⤷ Start Trial
Germany	3679116	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,324,824

Summary for Patent: 5,324,824